A Randomized Open Label Phase 2 Study of Denintuzumab mafodotin (SGN -CD19A)

Clinical Trial Grant

Duke Scholars

Principal Investigator Matthew Stuart McKinney Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Seattle Genetics, Inc

Start Date

May 23, 2016

End Date

February 18, 2019

Administered By

Duke Cancer Institute

Awarded By

Seattle Genetics, Inc

Start Date

May 23, 2016

End Date

February 18, 2019